ixekizumab · Taltz

Monoclonal antibody

Also known as LY2439821

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Non-radiographic Axial Spondyloarthritis TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
  • Ankylosing Spondylitis TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis.Outside this platform's coverage
Product first approved 2016FDA label
JP
  • Psoriasis (plaque psoriasis, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis) - Torutsu
Product first approved 2016yakuji.co.jp
CA
  • Plaque Psoriasis TALTZ (ixekizumab) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Psoriatic Arthritis TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). TALTZ can be used alone or in combination with a conventional DMARD (cDMARD) (e.g., methotrexate). Ankylosing Spondylitis TALTZ is indicated for the treatment of adult patients with active...
Product first approved 2016Health Canada
EU
  • Taltz: plaque psoriasis (initial); now also psoriatic arthritis and axial spondyloarthritis; holder Eli Lilly and Company (Ireland) Limited
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (26)
Psoriasis
NCT06588283 · Eli Lilly and Company
2024-09-30 – 2026-06-01 · Psoriasis, Obesity
What this study did
NCT03364309 · Eli Lilly and Company
2018-04-26 – 2020-06-04 · Plaque Psoriasis
What this study did
NCT02718898 · Eli Lilly and Company
2016-04 – 2018-02-21 · Genital Psoriasis, Psoriasis
What this study did
NCT02634801 · Eli Lilly and Company
2016-01-20 – 2017-11-14 · Plaque Psoriasis
What this study did
NCT02561806 · Eli Lilly and Company
2015-10 – 2017-10 · Plaque Psoriasis
What this study did
NCT01624233 · Eli Lilly and Company
2012-06 – 2017-09 · Psoriasis
What this study did
NCT02513550 · Eli Lilly and Company
2015-08 – 2017-08-03 · Plaque Psoriasis
What this study did
NCT02387801 · Eli Lilly and Company
2015-04 – 2016-08 · Psoriasis
What this study did
NCT01777191 · Eli Lilly and Company
2013-03 – 2015-05 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT06588296 · Eli Lilly and Company
2024-09-24 – 2026-04-23 · Psoriatic Arthritis, Obesity
What this study did
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT02584855 · Eli Lilly and Company
2015-09-14 – 2018-10-30 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT04285229 · Eli Lilly and Company
2020-04-10 – 2022-03-17 · Spondyloarthritis
What this study did
NCT04724629 · University of Sao Paulo
2021-01-05 – 2021-07-30 · Covid19
What this study did
NCT03129100 · Eli Lilly and Company
2017-05-09 – 2021-05-27 · Axial Spondyloarthritis
What this study did
NCT02757352 · Eli Lilly and Company
2016-08-02 – 2019-05-07 · Axial Spondyloarthritis
What this study did
NCT02696798 · Eli Lilly and Company
2016-04-12 – 2019-05-03 · Spondyloarthritis
What this study did
NCT02696785 · Eli Lilly and Company
2016-05-02 – 2018-10-17 · Spondyloarthritis
What this study did
NCT01870284 · Eli Lilly and Company
2014-07 – 2018-04 · Spondylitis, Ankylosing
What this study did
Phase 2/3 (1)
Psoriasis
NCT06374979 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-05 – 2026-06 · Guttate Psoriasis
What this study did
Phase 2 (8)
Psoriasis
NCT01107457 · Eli Lilly and Company
2010-04 – 2016-07 · Psoriasis
What this study did
Other / comorbidity
NCT04589325 · Göteborg University
2022-11-09 – 2027-12 · Type1 Diabetes Mellitus
What this study did
NCT05309616 · Yale University
2025-02-20 – 2026-05-19 · Idiopathic Subglottic Stenosis
What this study did
NCT04979910 · Icahn School of Medicine at Mount Sinai
2021-08-27 – 2024-04-12 · Major Depressive Disorder
What this study did
NCT03485976 · Oregon Health and Science University
2018-05-23 – 2020-01-13 · Pityriasis Rubra Pilaris
What this study did
NCT03099538 · Mayo Clinic
2017-08-15 – 2019-06-06 · Bullous Pemphigoid, Pemphigoid
What this study did
NCT03137160 · Ohio State University
2017-05-04 – 2018-08-16 · Pyoderma Gangrenosum
What this study did
NCT00966875 · Eli Lilly and Company
2009-08 – 2012-06 · Rheumatoid Arthritis
What this study did
Phase 1 (11)
Psoriasis
NCT03073213 · Eli Lilly and Company
2017-04-13 – 2019-05-14 · Psoriasis
What this study did
NCT02993471 · Eli Lilly and Company
2016-12-22 – 2017-11-21 · Psoriasis
What this study did
Other / comorbidity
NCT07789964 · Samsung Bioepis Co., Ltd.
2026-09-04 – 2027-06-09 · Healthy
What this study did
NCT07200986 · Celltrion
2025-09-17 – 2026-03-31 · Healthy Participants
What this study did
NCT05030415 · University of New Mexico
2021-08-12 – 2024-03-25 · Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris
What this study did
NCT04259346 · Eli Lilly and Company
2020-02-05 – 2021-02-19 · Healthy
What this study did
NCT03848403 · Eli Lilly and Company
2019-01-29 – 2019-07-18 · Healthy
What this study did
NCT03848416 · Eli Lilly and Company
2019-01-29 – 2019-06-07 · Healthy
What this study did
NCT02543918 · Eli Lilly and Company
2015-09 – 2015-12 · Healthy
What this study did
NCT01236118 · Eli Lilly and Company
2010-12 – 2013-01 · Rheumatoid Arthritis
What this study did
NCT01253265 · Eli Lilly and Company
2010-05 – 2011-12 · Rheumatoid Arthritis
What this study did
Phase 4 (11)
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT06398106 · University Hospital, Ghent
2024-12-20 – 2028-03-01 · Psoriasis Vulgaris
What this study did
NCT04537689 · Singapore General Hospital
2020-12-10 – 2027-12-31 · Plaque Psoriasis
What this study did
NCT04340076 · Radboud University Medical Center
2020-08-20 – 2025-01-31 · Psoriasis, Psoriasis Vulgaris
What this study did
NCT04083612 · University Hospital, Ghent
2020-05-04 – 2023-12-31 · Psoriasis Vulgaris
What this study did
NCT03942042 · Eli Lilly and Company
2019-07-05 – 2020-07-22 · Generalized Pustular Psoriasis, Erythrodermic Psoriasis
What this study did
NCT03573323 · Eli Lilly and Company
2018-11-09 – 2020-01-08 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT05855967 · Eli Lilly and Company
2023-06-27 – 2024-09-23 · Plaque Psoriasis, Psoriatic Arthritis
What this study did
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
NCT03151551 · Eli Lilly and Company
2017-08-24 – 2019-09-04 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT06085079 · Massachusetts Eye Research and Surgery Institution
2022-06-01 – 2024-12-30 · Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
What this study did
Early phase / not applicable (3)
Psoriasis
NCT06811558 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-02-01 – 2027-12-31 · Over 70-year-old Patients with Psoriasis
What this study did
NCT05042635 · Shanghai Yueyang Integrated Medicine Hospital
2021-10-01 – 2024-09-30 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT07443956 · NHS Greater Glasgow and Clyde
2026-03-09 – 2030-05 · Psoriatic Arthritis (PsA), Obesity & Overweight
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Psoriasis
NCT06945107 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2025-05-27 – 2027-01-19 · Plaque Psoriasis
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Psoriasis
NCT05503875 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-01-01 – 2027-12-31 · Immunoclassification, Psoriasis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Psoriasis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ixekizumab (Taltz): this drugApprovedMonoclonal antibodyIL-17Reliable signal
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
NCT01474512: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA) (Week 12): Ixe Q4W 76.4% | Ixe Q2W 81.8% vs Placebo 3.2%
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00195676: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed)
NCT00237887: REVEAL: PASI 75 response rates of 71% after 16 weeks and 70% after 24 weeks of treatment with adalimumab 40 mg every other week.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT03701763: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Apremilast 33.1% vs Placebo 11.5%
NCT03777436: Percentage of Participants With a Modified sPGA-G Response at Week 16 (Baseline and Week 16 of the Placebo-controlled Phase): Placebo-controlled Phase: Apremilast 30 mg 39.6% (95% CI 31.2 to 48) vs Placebo-controlled Phase: Placebo 19.5% (95% CI 12.7 to 26.3)
Betamethasone Dipropionate Emollient Spray (Sernivo)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03412747: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2%
NCT03370133: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W (RS) 85% vs Placebo (RS) 4.8% vs Ustekinumab (RS) 49.7%
Brodalumab (Siliq)ApprovedMonoclonal antibodyIL-17 receptor APartial signal
NCT02982005: Coprimary endpoints at week 12: PASI 75 and sPGA success achieved by 92.5% (brodalumab 210mg Q2W) vs 0% (placebo), significantly higher
Calcipotriene / Betamethasone Dipropionate Cream (Wynzora)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptorPartial signal
NCT03802344: Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9)
NCT03308799: PGA treatment success at week 8: 37.4% with CAL/BDP cream (MC2-01) vs 22.8% with CAL/BDP topical suspension (P<0.0001) and 3.7% with vehicle (P<0.0001) (Stein Gold et al., J Drugs Dermatol 2021).
Calcipotriene / Betamethasone Dipropionate Foam (Enstilar)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Calcipotriol / Betamethasone Dipropionate Gel (Taclonex)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaReliable signal
NCT02326298: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo).
NCT02326272: PASI 75 at Week 16 (CIMPASI-2): certolizumab pegol 200mg Q2W 81.4%, 400mg Q2W 82.6%, placebo 11.6% (P<0.0001 for both doses vs placebo).
Desoximetasone (Topicort Spray)ApprovedSmall moleculeGlucocorticoid receptor agonistPartial signal
NCT02618759: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 (28 Days): DSXS1505 10/60 (16.7%) vs Placebo 3/59 (5.1%) missed phase 3 result · pivotal pending
NCT02932462: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis (from baseline to study day 29): DSXS 1535 41/106 (38.7%) vs Placebo 43/126 (34.1%) missed phase 3 result · pivotal pending
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04167462: The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5)
NCT03611751: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1) (Week 16): BMS-986165 253/511 (49.5%) vs Placebo 22/255 (8.6%)
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Weak signal
NCT00111436: Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases.
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02203032: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001.
NCT02207244: Week 16 co-primary endpoints (VOYAGE 2, NCT02207244): IGA 0/1 84.1% guselkumab vs 8.5% placebo (p<0.001); PASI 90 70.0% guselkumab vs 2.4% placebo (p<0.001)
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptorReliable signal
NCT02742441: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4%
NCT02368210: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 25.3% vs Vehicle Foam 3.9%
Halobetasol Propionate Lotion (Bryhali)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT02514577: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13%
NCT02515097: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 38.41% vs IDP-122 Vehicle Lotion 11.99%
Halobetasol Propionate / Tazarotene (Duobrii)ApprovedSmall moleculeGlucocorticoid receptor + retinoic acid receptorPartial signal
NCT02462122: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 2): 45.3% vs 12.5%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
NCT02462070: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 1): 35.8% vs 7.0%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
Icotrokinra (Icotyde)ApprovedPeptideIL-23 receptorReliable signal
NCT06095115: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 64.7%
NCT06095102: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 56.7% vs Placebo 5.8%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01177800: PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001)
NCT00106847: Primary endpoint (PASI 75 at week 10), EXPRESS II trial -- official title fetched directly from the CT.gov API for this NCT matches word-for-word ('...Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Patients With Plaque-Type Psoriasis'): infliximab 3mg/kg 70%, 5mg/kg 75%, vs placebo 2% (P<0.001).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02672852: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001
NCT02684370: PASI90 at Week 16 (UltIMMa-1 trial, NCT02684370): risankizumab 75.3% vs placebo 4.9% vs ustekinumab 42.0% (p<0.0001 vs both comparators)
Roflumilast (Zoryve Foam)ApprovedSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Partial signal
NCT04211389: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%)
NCT04211363: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 (Baseline (Day 1) and Week 8): Rofumilast Cream 0.3% 108/255 (42.4%) vs Vehicle Cream 8/132 (6.1%)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01358578: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%)
NCT01365455: Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks (12 weeks): AIN457 150 mg 71.6% | AIN457 300 mg 81.6% vs Placebo 4.5%
Spesolimab (Spevigo)ApprovedMonoclonal antibodyIL-36 receptorReliable signal
NCT03782792: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Spesolimab 900 mg i.v SD 54.3% (95% CI 38.2% to 69.5%) vs Placebo 5.6% (95% CI 1% to 25.8%)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT03956355: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) 35.4% (Standard Error 2.75) vs Vehicle Cream 6% (Standard Error 2.08)
NCT03983980: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) Cream Group 40.2% (Standard Error 2.82) vs Vehicle Cream Group 6.3% (Standard Error 1.99)
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT01722331: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8%
NCT01729754: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1) (Week 12): Tildrakizumab 200 mg 65.6% | Tildrakizumab 100 mg 61.2% vs Placebo 5.8% | Etanercept 50 mg 48.2%
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT00307437: PASI 75 at Week 12 (intent-to-treat, PHOENIX 2 trial): placebo 15/410 vs ustekinumab 45 mg 273/409 vs ustekinumab 90 mg 311/411; p<0.001 for each dose vs placebo.
NCT00267969: PASI 75 at week 12: ustekinumab 45mg 67.1% vs placebo 3.1% (difference 63.9%, 95% CI 57.8-70.1, p<0.0001); ustekinumab 90mg 66.4% vs placebo 3.1% (difference 63.3%, 95% CI 57.1-69.4, p<0.0001).
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40Reliable signalFeatured results are non-efficacy only in this race
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Amdokitug (Yisaituo)Phase 3Monoclonal antibodyIL-17Anot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Skilarence)Phase 3Small moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
EbdarokimabPhase 3Monoclonal antibodyIL-12/23 p40not yet gradedNo reviewed efficacy summary in this indication
EnvudeucitinibPhase 3Small moleculeTYK2Reliable signal
NCT06586112: PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all)
NCT06588738: ONWARD2, week 16 co-primary endpoints vs placebo (intention-to-treat, nonresponder imputation): PASI 75 70.4% with envudeucitinib 40 mg twice daily (n=433) vs 13.7% with placebo (n=211); sPGA 0/1 57.3% vs 5.7%; both P < 0.0001 (Cochran-Mantel-Haenszel). PASI 90: 53.1% vs 4.3%. Apremilast 30 mg twice daily (n=215): PASI 75 38.6%, sPGA 0/1 27.4% (Alumis AAD 2026 late-breaking presentation).
FadeucravacitinibPhase 3Small moleculeTYK2Partial signal
NCT06109818: PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved
GumokimabPhase 3Monoclonal antibodyIL-17APartial signal
NCT06066125: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7%
HB0017Phase 3Monoclonal antibodyIL-17APartial signal
NCT05531682: Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens.
HS-10374Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-20137Phase 3Monoclonal antibodyIL-23 p19not yet gradedNo reviewed efficacy summary in this indication
ImsidolimabPhase 3Monoclonal antibodyIL-36 receptorPartial signalFeatured results are non-efficacy only in this race
LecankitugPhase 3Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4Partial signal
NCT04839328: PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%)
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03390101: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%)
Nomelcitinib (D-2570)Phase 3Small moleculeTYK2Partial signal
NCT06278350: Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001)
PicankibartPhase 3Monoclonal antibodyIL-23 p19Reliable signal
NCT06049810: PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons
NCT05645627: Co-primary 1, PASI 90 at week 16: 80.3% picankibart 200 mg vs 2.0% placebo (p<0.0001), met. Co-primary 2, sPGA 0/1 at week 16: 93.5% vs 13.1% (p<0.0001), met. Response rates from the JAAD paper; p-values from the Innovent release, as the paper abstract does not print them.
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 3Small moleculeTYK2Partial signal
NCT06542614: At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks
VunakizumabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT04839016: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025).
NCT03463187: PASI 75 at week 12: 56.8% (40 mg), 65.8% (80 mg), 81.6% (160 mg), and 86.5% (240 mg) vs 5.4% placebo; P < .001 for all
ZasocitinibPhase 3Small moleculeTYK2Reliable signal
NCT06973291: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib.
NCT06088043: Co-primary 1, sPGA 0/1 at week 16: 71.4% zasocitinib vs 10.7% placebo (p<0.001), met. Co-primary 2, PASI 75 at week 16 vs placebo: superiority shown per Takeda's topline release (response rates and p not printed in Takeda's releases), met. Ranked secondary, PASI 90 at week 16: 61.3% vs 5.0% placebo and 16.8% apremilast (p<0.001).
SonelokimabPhase 2Antibody-derived scaffoldIL-17A/FReliable signal
NCT03384745: Primary endpoint, IGA 0/1 at week 12: placebo 0.0%, sonelokimab 30mg 48.1% (p<0.0001), 60mg 84.6% (p<0.0001), 120mg normal load 77.4% (p<0.0001), 120mg augmented load 88.2% (p<0.0001), secukinumab 300mg (active reference) 77.4% (p<0.0001) vs placebo.
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 69 furthest-along competitors are listed; 50 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Taltz (ixekizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
February 2027 (1)
Phase 2Type1 Diabetes MellitusActive not recruiting
Est. primary completion 2027-02 · NCT04589325 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1HealthyRecruiting
Est. primary completion 2027-06-09 · NCT07789964 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4PsoriasisRecruiting
Est. primary completion 2027-12-31 · NCT04537689 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Early phase / not applicablePsoriatic ArthritisRecruiting
Est. primary completion 2028-02 · NCT07443956 · CT.gov ↗
What to watch
March 2028 (1)
Phase 4PsoriasisRecruiting
Est. primary completion 2028-03-01 · NCT06398106 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch

See the full readout calendar ↗